For each case, data concerning karyotype success rates (defined as fetal cell growth sufficient to undergo karyotype analysis), training level of collecting provider, time from IUFD diagnosis to sample collection, and cost of laboratory testing were extracted. RESULTS: Charts from 71 patients with a diagnosis of IUFD were reviewed. In total, 35 placental specimens and 14 fascia lata specimens were collected. Of these samples, 80% of the placental and 21% of the fascia lata samples successfully grew cells for karyotype (p¼<0.01). In cases where both fascia lata and placental specimens were collected, there were no instances where the fascia lata successfully yielded cells for karyotype when the placental specimen was unsuccessful. There was no difference in karyotype success rates when comparing specimens collected by more experienced providers (more than 2 years of training) or less experienced providers (p¼0.29; RR¼0.77; CI¼0.47-1.3). Time from diagnosis to sample collection was not predictive of karyotype success rates in this study. Cost of tissue culture and karyotyping was $2,151 for either a placental or fascia lata specimen, or $4,302 for both. CONCLUSION: At our institution, placental samples have a significantly higher karyotype success rate compared to fascia lata specimens, regardless of provider experience or time from diagnosis to sample collection. This study supports the prioritization of placental specimen collection over fascia lata, especially in settings where routine amniocentesis for IUFD is unavailable. This study also shows that there is a significant cost saving without benefit loss in collecting only placental specimens compared to collecting both fascia lata and placental samples.
381 Detection of substance use in pregnant women using the 4Ps questionnaire Virginia Commonwealth University, Richmond, VA OBJECTIVE: Professional organizations recommend universal drug screening using a tool such as the "4Ps" ( Pregnancy, Past, Partner, and Parental Use) to identify risk factors for substance abuse. This screening tool has been validated in non-pregnant subjects but not in pregnancy. Our objective was to evaluate the relationship between the "4Ps" screening tool and a concurrent urine drug screen for identification of substance use in pregnancy. STUDY DESIGN: This is a prospective cohort study of women receiving prenatal care in a community-based university -affiliated hospital clinic. Patients who were incarcerated, enrolled in a substance use program, under 18 years, non-English/Spanish speaking, intellectually disabled, or unwilling to provide a urine sample were excluded. Consenting subjects completed a de-identified demographic questionnaire, a 4Ps questionnaire, and provided a urine sample at their initial prenatal visit. Urine specimens were analyzed for nine illicit substances using SYVAÒ EMITÒ assays on Beckman Coulter AU 680. RESULTS: One hundred seventy seven women were screened with 4Ps and urine drug screen, of whom 30 (16.9%) had a positive 4Ps screen and 40 (22.6%) had a positive urine drug screen. Four urine drug screens were positive for more than one substance. Marijuana was the most commonly detected substance (n¼39), followed by cocaine (3), oxycodone (2), amphetamines (1) and benzodiazepine (1). Test characteristics are depicted in Table 1 . CONCLUSION: The 4Ps questionnaire has low sensitivity and positive predictive value for current substance abuse in pregnancy and is an inadequate screening test. Given the prevalence and perinatal implications of substance use in pregnancy, the development of a validated screening tool is needed.
382 Weight retention after pregnancies and risk of cesarean delivery in subsequent pregnancies
Tetsuya Kawakita
MedStar Washington Hospital Center, Washington, DC OBJECTIVE: Many women have difficulty in losing the weight gained during pregnancies. Obese women are often counseled to reduce weight prior to conception. However, the impact of weight gain between pregnancies on subsequent pregnancies is not well studied. We sought to examine the rate of cesarean delivery according to weight gain between pregnancies. STUDY DESIGN: This was a retrospective cohort study of all multiparous women with singleton pregnancies and cephalic presentation delivering at 23 weeks' gestation between 2009 and 2017 at an urban institution. Women with missing data and a history of cesarean delivery were excluded. Analyses were limited to obese women with more than one pregnancy in the dataset. For women with more than two pregnancies, only first and second pregnancies were analyzed. Obesity was defined as a prepregnancy body mass index (BMI) 30 kg/m 2 before the first pregnancy. Weight retention was defined as an increase in BMI between pregnancies by more than 1 kg/m 2 . Our primary outcome was the rate of cesarean delivery. A multivariable logistic regression analysis was performed to calculate an adjusted odds ratio (OR) and 95% confidence interval (95%CI), controlling for predefined covariates (age, race/ethnicity, and the number of previous vaginal births). RESULTS: Of 226 obese women, there were 137 (60.6%) women without weight retention and 89 (39.4%) women with weight retention. There was no difference in prepregnancy BMI before the first pregnancy (P ¼.24). However, in the second pregnancy, women with weight retention compared to women without weight retention were more likely to have higher BMI at admission (P <.001), gestational diabetes (8.3% vs. 2.3%; unadjusted P¼.04), and chronic hypertension (19.1% vs. 9.4%; unadjusted P ¼.04) (Table) . After controlling for confounders, women with weight retention compared to women without weight retention were more likely to have a cesarean delivery (20.2% vs. 4.7%; unadjustedP<.001; adjusted OR 5.27; 95%CI 1.86-14.9) (Figure) . CONCLUSION: In our cohort of multiparous women without a history of cesarean delivery, more than a third of women had weight retention after first pregnancy. Given increased odds of cesarean delivery associated with weight retention even in multiparous women, our data support the recommendations to lose weight before conception in obese women. OBJECTIVE: External cephalic version (ECV) is a technique used to reduce the incidence of cesarean deliveries due to malpresentation. Nitrous oxide is used for pain relief for women undergoing ECV. We compared the mode of delivery and success rate in ECV with and without nitrous oxide. STUDY DESIGN: A retrospective cohort analysis was performed including all singleton, term ECVs between January 2016 to June 2017 at a single institution. Multivariable logistic regression was used to compare the success rates in women who had ECV without nitrous oxide versus ECV with nitrous oxide. The primary outcome was rate of ECV success and secondary outcome was rate of vaginal delivery. RESULTS: During the study period, 167 women underwent ECV: 90 without nitrous oxide and 77 with nitrous oxide. 29 (32.2%) of the women without nitrous were successfully converted to cephalic presentation and 8 of these delivered vaginally (27.6%). Of the 77 women who used nitrous, 25 (32.5%) were successful and 8 of these women delivered vaginally (32.2%) (RR 1.00 for rate of conversion, 95% CI 0.6-1.5). After controlling for confounders, use of nitrous oxide had no clinically or statistically significant difference on ECV success rates (OR 1.08, 95% CI 0.52-2.23). CONCLUSION: Nitrous oxide does not seem to affect the success of ECV. More research should be done to determine whether use of nitrous oxide improves patient satisfaction and tolerability of ECV. 
OBJECTIVE:
The number of women of advanced maternal age (AMA), defined as age 35 years or greater, is increasing in the United States. While AMA women have increased risks for pregnancy complications from increased underlying comorbidities, little is known regarding specific risk factors for postpartum readmissions and associated complications. We evaluated the risk factors for postpartum readmissions and the associated severe morbidity in this population during their 'fourth trimester' . STUDY DESIGN: Using the Nationwide Readmission Database, the 60-day all-cause postpartum readmission risk from 2010 to 2014 was analyzed. Risk for severe morbidity (SMM) during readmission was ascertained using criteria from the Centers for Disease Control and Prevention. The primary exposure of interest was maternal age (15-18, 19-24, 25-34, 35-39, 40-44, and >44 years) . Outcomes included time to readmission, risk of readmission, and risk for SMM during readmission. Multivariable log linear analyses adjusting for patient, obstetric, and hospital factors were conducted to assess these outcomes using risk ratios (RR) with 95% confidence intervals (CI). RESULTS: Between 2010-2014, we identified 15.3 million deliveries, 15% of which were to women aged 35 or older. The 60-day all-cause readmission rate was 1.8%. Of these, 12% were complicated by SMM. Age-stratification revealed that AMA patients had significantly longer readmission lengths of stay, increased risk for readmission, and increased risk for SMM. The majority of readmissions occurred within the first 20 days regardless of age (Figure 1) . In multivariable analysis, AMA patients ages 35-39, 40-44, and >44 years had 11% (RR 1.11, 95% CI 1.09, 1.12), 30% (RR 1.30, 95% CI 1.28, 1.32), and 46% (RR 1.46, 95% CI 1.36, 1.56) significantly higher rates of allcause readmission when compared to 25-34 year old patients. Women 35-39, 40-44, and >44 years of age had a 19% (95% CI 14-25%), 50% (95% CI 41-59%), and 84% (95% CI 48-131%) higher risk of a readmission with SMM than women 25-34 (Table 1) . CONCLUSION: AMA women are at higher risk for both postpartum readmission and severe morbidity during readmission. Women older than 35 years represent the group most likely to experience complications requiring readmission, with the sharpest risk increase after
